Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry

European Heart Journal

Volumn 28, Issue 8, 2007, Pages 980-988

  Gheorghiade, Mihai ^a   Abraham, William T ^b   Albert, Nancy M ^c   Gattis Stough, Wendy ^d,e   Greenberg, Barry H ^f   O'Connor, Christopher M ^d   She, Lilin ^g   Yancy, Clyde W ^h   Young, James ^c   Fonarow, Gregg C ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e CAMPBELL UNIVERSITY   (United States)

^f UCSD MEDICAL CENTER   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UCLA MEDICAL CENTER   (United States)

Author keywords

Heart failure; Hospitalization; Registry; Risk factors; Serum sodium

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; STATIN; THIAZIDE DIURETIC AGENT; VASOACTIVE AGENT; WARFARIN;

AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; HYPONATREMIA; INOTROPISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CHRONIC DISEASE; DIURETICS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SODIUM; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34548348725     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl542     Document Type: Article

References (21)

1. Kumar S, Berl T. Sodium. Lancet 1998;352:220-228.
2. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005;95:2B-7B.
3. Goh KP. Management of hyponatremia. Am Fam Physician 2004;69:2387-2394.
4. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-1589.
5. Klein L, O' Connor CM, Leimberger JD, Gattis-Stough, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-2460.
6. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971.
7. Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, Baig W, Lindsay S, Callahan TS, Shell WE, Eckberg DL, Zaman AG, Williams S, Neilson JM, Nolan J. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 2002;40:1801-1808.
8. Senni M, De Maria R, Gregori D, Gonzini L, Gorini M, Cacciatore G, Gavazzi A, Pulignano G, Porcu M, Maggioni AP. Temporal trends in survival and hospitalizations in outpatients with chronic systolic heart failure in 1995 and 1999. J Card Fail 2005;11:270-278.
9. Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF Jr, Gheorghiade M, O'Connor CM. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004;10:460-466.
10. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002;162:1682-1688.
11. Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O'Connor CM, Yancy CW, Young J. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004;148:43-51.
12. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Gattis WA, Yancy CW, Young JB, Fonarow GC, for the OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217-2226.
13. Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J Clin Endocrinol Metab 1984;59:924-930.
14. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-267.
15. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996;156:1814-1820.
16. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581-2587.
17. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-2696.
18. Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C, for the Tolvaptan Investigators. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006;97:1064-1067.
19. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin-receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91:2145-2152.
20. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112.
21. Gheorghiade M, Orlandi C, Burnett JC, DeMets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005;11:260-269.